drama high pharmaceutical drug prices marketing behavior big pharma biz medicalization american society little said generic drug business i discussed piece dsm absurdly high anti depressant profit attributed pharmaceutical industry one highlights inexpensive well researched recommended antidepressant drugs weekend i got call friend taking antidepressant told me cost went medication taking insurance plan psychiatrist knows practically impossible advise patient end paying extended release version venlafaxine even though generic attempt find online results confusing blend american canadian prices canadian prices list exceed would paid i caught article hirst reproduced local paper weekend describes patient taking generic carbamazepine carbamazepine generic years i recall prescribing generic years ago patients bipolar disorder patient taking medication epilepsy getting drug walgreen prescription savings club paying three month supply recently price increased forced buy month month basis drug information suggests least generic manufacturers original name brand along sustained release patented version current market senator bernie sanders i vt quoted wanted know rational economic reason patients saw price increases whether simply question greed federal government tightly regulates health care special attention department justice could dramatic price increases face ample competition matter greed would need cooperative effort part competitors drive prices fast article cites raw material shortages consolidation industry medical advances make replicating brand name drugs expensive i accept explanation greed one expensive medications manufacture recent times atorvastatin first came i spoke scientists involved production told me cost per pill manufacture cost small fraction overall prescription price leads me believe even month prescription ranitidine lead profits generic manufacturer hirst article quotes pharmacy benefit manager saying average cost generic drug prescription increased available generics cost per prescription another consultant suggested acquisition costs pharmacies increased past year academic article available new england journal medicine alpern et al authors look specific example albendazole broad spectrum anti parasitic long expired patent average wholesale price awp single day dose authors look national drug acquisition costs file cite number significant price increases widely known generic drugs including captopril clomipramine digoxin doxycyline produced excellent graphic looks number prescriptions global medicaid budget mobendazole albendazole factors led significant price increases latter case seems like lack competition limiting factor authors cite drug shortages supply disruptions consolidations within generic drug industry factors decrease competition therefore may increase prices also described generic drug approval process slowing competition especially market delay implementation generic cost additional tens hundreds millions dollars nejm article chicago tribune article supply side emphasis adequate competition innovation free market increasing supply driving prices lower maintaining high value consumers another story demand pharmaceuticals relatively inelastic means price increases buyers postpone purchases better day without risk significant cases life threatening consequences inelasticity compounded several recent factors lead complications first advent high deductible health insurance plans majority employers use plans largely managed care failed contain costs costs employees generally shifted risk pool subsequent year puts anyone high deductibles significant risk pocket costs deductible satisfied drug manufacturer expect receive significant pocket payments deductible applies second advent tiered coverage based insurance plan usually involves steeper copay insurance plan covers less real risk patient may decide simply forgo prescription point reached good chance pay significantly lowest generic price drug class current system government sanctioned managed care inelastic pharmaceutical demand places americans financial risk since essentially tax many ways entitlement health care companies including generic drug manufacturers obvious factor none authors comment pharmaceuticals remain top selling drugs despite fact generics cases like advair diskus drug unique delivery system also patented anyone using advair likely want continue use delivery system whether generic drug price remains high another example asthma care numerous metered dose inhalers underwent regulatory change propellants chlorofluorcarbons cfcs hydrofluoralkanes hfas accompanies patent immediate significant price hike anyone using inhalers i think trend instructive number reasons first illustrates come pricing pharmaceutical product complex monopoly power clearly market forces play escalate prices drugs around well past patent expiration date conversely many medications pricing power concern patients physicians longer manufactured easy understand generic drug manufacturers unwilling maintain large inventory wal mart walgreens per month formulary second shows potential significant distortion markets introduced managed care companies government counterparts rather idealized cost effectiveness arrangements anything cost effective example saving pharmacy costs explode cost care another direction case point significantly gone period blaming name brand pharmaceutical industry otherwise known big pharma number problems blamed inadequate disclosure clinical trials data distortion clinical trials data ghost writing articles physicians misleading marketing practices critics also usual complaints efficacy side effects seem miss regulatory goal getting relatively safe effective perfect drug market use seem get pass influence fda fact critics seem think create idealized regulatory agency free political influence critics seem suspend reality pharmaceutical companies businesses people science end businesses likelihood idea going business end explicit motivation according critics money fuel businesses generic drug industry little pharma much smaller marketing infrastructure research development costs much less detailing physicians recently viewed saviors patient little resources definite positive every managed care company looking enhance bottom line lower pharmacy costs antidote big pharma despite positive spin price increase years generic drugs i think i going far limb say generic albendazole may one profitable medications ever made politicians starting make noise physicians implicated like big pharma scandals i see nothing coming washington would surprise me real silence seems big pharma critics generic drug industry real explanation huge price increases least nothing easily attribute instead saying big pharma unconsciously influences physicians prescribing expensive drugs hundreds thousands physicians consciously trying prescribe least expensive drugs patients failing regular basis maybe appearance conflict interest quite theory cracked pharmascolds theories george dawson md dfapa refs ellen jean hirst generic drug prices skyrocket past year supposed top cheaper market forces intervened chicago tribune alpern jd stauffer wm kesselheim high cost generic drugs implicationsfor patients policymakers engl med nov doi nejmp pubmed pmid national drug acquisition costs page multiple files large document pages medications listed ndc number sample click graphic discover aripiprazole abilify expensive medication